Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEnalaprilat
Identification
- Name
- Enalaprilat
- Accession Number
- DB09477
- Type
- Small Molecule
- Groups
- Approved
- Description
Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume. Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth. Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.
Enalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible.
- Structure
Structure for DB09477 (Enalaprilat)
- Synonyms
- Enalaprilat anhydrous
- Product Ingredients
Ingredient UNII CAS InChI Key Enalaprilat dihydrate GV0O7ES0R3 84680-54-6 MZYVOFLIPYDBGD-MLZQUWKJSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Enalaprilat Injection USP Solution 1.25 mg Intravenous Sterimax Inc 2012-09-10 Not applicable Canada 
Vasotec IV Solution 1.25 mg Intravenous Sandoz Canada Incorporated 1992-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Enalaprilat Injection 1.25 mg/mL Intravenous Cardinal Health 2000-08-23 2017-11-14 US 
Enalaprilat Injection, solution 1.25 mg/mL Intravenous Teva Parenteral Medicines, Inc. 2005-10-06 Not applicable US Enalaprilat Injection 1.25 mg/mL Intravenous West Ward Pharmaceutical 2008-12-23 Not applicable US Enalaprilat Injection, solution 1.25 mg/mL Intravenous Teva Parenteral Medicines, Inc. 2005-10-06 Not applicable US Enalaprilat Injection 2.5 mg/2mL Intravenous West Ward Pharmaceutical 2008-12-23 Not applicable US Enalaprilat Injection, solution 1.25 mg/mL Intravenous Hospira, Inc. 2000-08-22 Not applicable US - Categories
- UNII
- Q508Q118JM
- CAS number
- 76420-72-9
- Weight
- Average: 348.3936
Monoisotopic: 348.168521888 - Chemical Formula
- C18H24N2O5
- InChI Key
- LZFZMUMEGBBDTC-QEJZJMRPSA-N
- InChI
- InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
- IUPAC Name
- (2S)-1-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]pyrrolidine-2-carboxylic acid
- SMILES
- [H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O
Pharmacology
- Indication
Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical.
- Associated Conditions
- Pharmacodynamics
Enalaprilat injection results in the reduction of both supine and standing systolic and diastolic blood pressure, usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients. The onset of action usually occurs within fifteen minutes of administration with the maximum effect occurring within one to four hours. The abrupt withdrawal of enalaprilat has not been associated with a rapid increase in blood pressure. The duration of hemodynamic effects appears to be dose-related. However, for the recommended dose, the duration of action in most patients is approximately six hours. Following administration of enalapril, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.
- Mechanism of action
Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume
Target Actions Organism AAngiotensin-converting enzyme inhibitorHuman UB1 bradykinin receptor Not Available Human - Absorption
Enalaprilat is poorly absorbed following oral administration, and is therefore only available as an intravenous injection.
- Volume of distribution
- Not Available
- Protein binding
Enalaprilat is approximately 50% bound to plasma proteins. (Davies, et al. 1984)
- Metabolism
Both enalapril and enalaprilat undergo renal excretion without further metabolism.
- Route of elimination
Excretion of enalaprilat is primarily renal with more than 90 percent of an administered dose recovered in the urine as unchanged drug within 24 hours.
- Half life
11 hr
- Clearance
The disposition of enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. Renal clearance was 158 ± 47 ml/min.
- Toxicity
Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: myocardial infarction, fatigue, dizziness, fever, rash and constipation. Angioedema has also been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately .
Rarer adverse effects that are less likely, but should be monitored for, include development of anaphylaxis, hypotension, agranulocytosis, hepatic failure, hyperkalemia, and persistent cough.
Furthermore, ACE inhibitors should be avoided during pregnancy as they can cause fetal and neonatal morbidity and death. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. Use during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Enalaprilat. Investigational 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Enalaprilat. Experimental Abacavir The serum concentration of Abacavir can be decreased when it is combined with Enalaprilat. Approved, Investigational Acebutolol Acebutolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Enalaprilat. Approved, Investigational Acemetacin The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acetylsalicylic acid The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Acetylsalicylic acid. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Enalaprilat. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Enalaprilat. Approved, Withdrawn Aldesleukin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Aldesleukin. Approved Alfuzosin The serum concentration of Alfuzosin can be increased when it is combined with Enalaprilat. Approved, Investigational Aliskiren Aliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Enalaprilat. Approved, Investigational Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Enalaprilat. Approved Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Enalaprilat. Experimental Alogliptin The risk or severity of adverse effects can be increased when Alogliptin is combined with Enalaprilat. Approved Aloxiprin The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Aloxiprin. Experimental Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Enalaprilat. Approved, Illicit, Investigational Alprenolol Alprenolol may increase the hypotensive activities of Enalaprilat. Approved, Withdrawn Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Ambrisentan Enalaprilat may increase the hypotensive activities of Ambrisentan. Approved, Investigational Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Enalaprilat. Experimental, Investigational Amifostine Enalaprilat may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride Amiloride may increase the hyperkalemic activities of Enalaprilat. Approved Amineptine The serum concentration of Amineptine can be increased when it is combined with Enalaprilat. Illicit, Withdrawn Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Enalaprilat. Approved Aminosalicylic Acid The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Aminosalicylic Acid. Approved Amiodarone The risk or severity of adverse effects can be increased when Amiodarone is combined with Enalaprilat. Approved, Investigational Amitriptyline The serum concentration of Amitriptyline can be increased when it is combined with Enalaprilat. Approved Amitriptylinoxide The serum concentration of Amitriptylinoxide can be increased when it is combined with Enalaprilat. Approved, Investigational Amlodipine Amlodipine may increase the hypotensive activities of Enalaprilat. Approved Amobarbital Amobarbital may increase the hypotensive activities of Enalaprilat. Approved, Illicit Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Enalaprilat. Approved Amphetamine Amphetamine may increase the hypotensive activities of Enalaprilat. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Enalaprilat. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Enalaprilat is combined with Amyl Nitrite. Approved Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Enalaprilat. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Enalaprilat. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Enalaprilat. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Enalaprilat. Investigational Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Enalaprilat. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Apraclonidine. Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Enalaprilat. Approved, Investigational Aprotinin Aprotinin may decrease the antihypertensive activities of Enalaprilat. Approved, Investigational, Withdrawn Aripiprazole Aripiprazole may increase the hypotensive activities of Enalaprilat. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Enalaprilat. Investigational Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Enalaprilat. Approved, Investigational Atenolol Atenolol may increase the hypotensive activities of Enalaprilat. Approved Atorvastatin The risk or severity of adverse effects can be increased when Atorvastatin is combined with Enalaprilat. Approved Avanafil Avanafil may increase the antihypertensive activities of Enalaprilat. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Enalaprilat. Withdrawn Azathioprine The risk or severity of anemia and severe leukopenia can be increased when Enalaprilat is combined with Azathioprine. Approved Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Enalaprilat. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalaprilat. Approved, Investigational Azosemide Azosemide may increase the hypotensive activities of Enalaprilat. Investigational Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Enalaprilat. Approved, Investigational Barbexaclone Barbexaclone may increase the hypotensive activities of Enalaprilat. Experimental Barbital Barbital may increase the hypotensive activities of Enalaprilat. Illicit Barnidipine Enalaprilat may increase the antihypertensive activities of Barnidipine. Approved Benazepril Benazepril may increase the hypotensive activities of Enalaprilat. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Enalaprilat. Experimental Bendroflumethiazide The risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Enalaprilat. Approved Benmoxin Benmoxin may increase the hypotensive activities of Enalaprilat. Withdrawn Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Enalaprilat. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Enalaprilat. Withdrawn Benzthiazide The risk or severity of hypotension can be increased when Benzthiazide is combined with Enalaprilat. Approved Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Enalaprilat. Approved Bepridil Bepridil may increase the hypotensive activities of Enalaprilat. Approved, Withdrawn Betaxolol Betaxolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Enalaprilat. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Enalaprilat. Experimental Bietaserpine Bietaserpine may increase the hypotensive activities of Enalaprilat. Experimental Bimatoprost Bimatoprost may increase the hypotensive activities of Enalaprilat. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Enalaprilat. Approved Boceprevir The serum concentration of Enalaprilat can be decreased when it is combined with Boceprevir. Approved, Withdrawn Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Enalaprilat. Approved, Investigational Bosentan Bosentan may increase the hypotensive activities of Enalaprilat. Approved, Investigational BQ-123 Enalaprilat may increase the hypotensive activities of BQ-123. Investigational Bretylium Bretylium may increase the hypotensive activities of Enalaprilat. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Enalaprilat. Approved Brofaromine Brofaromine may increase the hypotensive activities of Enalaprilat. Experimental Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Enalaprilat. Approved Bromocriptine The serum concentration of Bromocriptine can be increased when it is combined with Enalaprilat. Approved, Investigational Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Enalaprilat. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Enalaprilat. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Enalaprilat. Experimental Bumetanide Bumetanide may increase the hypotensive activities of Enalaprilat. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Enalaprilat. Approved, Investigational Bupranolol Bupranolol may increase the hypotensive activities of Enalaprilat. Approved Butriptyline The serum concentration of Butriptyline can be increased when it is combined with Enalaprilat. Approved Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Enalaprilat. Approved Cadralazine Cadralazine may increase the hypotensive activities of Enalaprilat. Experimental Cafedrine Enalaprilat may increase the hypotensive activities of Cafedrine. Investigational Calcium Carbonate Calcium Carbonate can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Canagliflozin The risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Enalaprilat. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Enalaprilat. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Enalaprilat. Approved Candoxatril Candoxatril may increase the hypotensive activities of Enalaprilat. Experimental Captopril Captopril may increase the hypotensive activities of Enalaprilat. Approved Carbaspirin calcium The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Carbaspirin calcium. Experimental, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Enalaprilat. Approved, Investigational Caroxazone Caroxazone may increase the hypotensive activities of Enalaprilat. Withdrawn Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Enalaprilat. Approved, Vet Approved, Withdrawn Carvedilol Carvedilol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Enalaprilat. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Enalaprilat. Approved, Investigational Celiprolol Celiprolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Enalaprilat. Approved, Investigational, Vet Approved Chlorothiazide The risk or severity of hypotension can be increased when Chlorothiazide is combined with Enalaprilat. Approved, Vet Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalaprilat. Approved, Investigational, Vet Approved Chlorthalidone The risk or severity of hypotension can be increased when Chlorthalidone is combined with Enalaprilat. Approved Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Enalaprilat. Approved Cicletanine Enalaprilat may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Cilazapril may increase the hypotensive activities of Enalaprilat. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Enalaprilat. Approved, Investigational Ciprofloxacin The risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Ciprofloxacin. Approved, Investigational Clarithromycin The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalaprilat. Approved Clevidipine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Clevidipine. Approved, Investigational Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Enalaprilat. Approved, Investigational Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Enalaprilat. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Enalaprilat. Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Enalaprilat. Approved Cloranolol Enalaprilat may increase the hypotensive activities of Cloranolol. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Enalaprilat. Approved Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Enalaprilat. Approved, Investigational Cryptenamine Cryptenamine may increase the hypotensive activities of Enalaprilat. Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Enalaprilat. Approved, Investigational Cyclopenthiazide The risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Enalaprilat. Experimental Cyclophosphamide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Cyclosporine. Approved, Investigational, Vet Approved Dapagliflozin The risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Enalaprilat. Approved Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Enalaprilat. Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Enalaprilat. Approved, Investigational Delapril Enalaprilat may increase the hypotensive activities of Delapril. Investigational Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Enalaprilat. Approved Dersalazine The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Dersalazine. Investigational Deserpidine Enalaprilat may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Enalaprilat. Approved Desipramine The serum concentration of Desipramine can be increased when it is combined with Enalaprilat. Approved, Investigational Dexmedetomidine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dexmedetomidine. Approved, Vet Approved Dexniguldipine Enalaprilat may increase the hypotensive activities of Dexniguldipine. Experimental Diazoxide Diazoxide may increase the hypotensive activities of Enalaprilat. Approved Dibenzepin The serum concentration of Dibenzepin can be increased when it is combined with Enalaprilat. Experimental Diclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Enalaprilat. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Diclofenamide. Approved, Investigational Diethylnorspermine Diethylnorspermine may increase the hypotensive activities of Enalaprilat. Investigational Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalaprilat. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Enalaprilat. Experimental Diflunisal The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Diflunisal. Approved, Investigational Digoxin The serum concentration of Digoxin can be increased when it is combined with Enalaprilat. Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Dihydroergotamine The serum concentration of Dihydroergotamine can be increased when it is combined with Enalaprilat. Approved, Investigational Diltiazem Diltiazem may increase the hypotensive activities of Enalaprilat. Approved, Investigational Dimetacrine The serum concentration of Dimetacrine can be increased when it is combined with Enalaprilat. Approved, Withdrawn Dinutuximab The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dinutuximab. Approved, Investigational Dipyridamole The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dipyridamole. Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Enalaprilat. Approved Dosulepin The serum concentration of Dosulepin can be increased when it is combined with Enalaprilat. Approved Doxazosin Doxazosin may increase the hypotensive activities of Enalaprilat. Approved Doxepin The serum concentration of Doxepin can be increased when it is combined with Enalaprilat. Approved, Investigational Drospirenone Enalaprilat may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Enalaprilat. Withdrawn Duloxetine Enalaprilat may increase the orthostatic hypotensive activities of Duloxetine. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Enalaprilat. Investigational Dyphylline The serum concentration of Dyphylline can be decreased when it is combined with Enalaprilat. Approved E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Enalaprilat. Investigational Efonidipine Efonidipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Empagliflozin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Empagliflozin. Approved Enalapril Enalapril may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Endralazine Endralazine may increase the hypotensive activities of Enalaprilat. Experimental Enfuvirtide The serum concentration of Enfuvirtide can be increased when it is combined with Enalaprilat. Approved, Investigational Epanolol Enalaprilat may increase the hypotensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Enalaprilat. Approved Epitizide The risk or severity of hypotension can be increased when Epitizide is combined with Enalaprilat. Experimental Eplerenone Eplerenone may increase the hyperkalemic activities of Enalaprilat. Approved Epoprostenol Epoprostenol may increase the hypotensive activities of Enalaprilat. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Enalaprilat. Approved Ergoloid mesylate The serum concentration of Ergoloid mesylate can be increased when it is combined with Enalaprilat. Approved Ergonovine The serum concentration of Ergonovine can be increased when it is combined with Enalaprilat. Approved Ergotamine The serum concentration of Ergotamine can be increased when it is combined with Enalaprilat. Approved Esmolol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Esmolol. Approved Estradiol The serum concentration of Estradiol can be decreased when it is combined with Enalaprilat. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Estradiol cypionate can be decreased when it is combined with Enalaprilat. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Estradiol valerate can be decreased when it is combined with Enalaprilat. Approved, Investigational, Vet Approved Etacrynic acid Etacrynic acid may increase the hypotensive activities of Enalaprilat. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Enalaprilat. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Enalaprilat. Experimental Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalaprilat. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Enalaprilat. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Enalaprilat. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Enalaprilat. Approved, Investigational Etravirine The serum concentration of Etravirine can be decreased when it is combined with Enalaprilat. Approved Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Enalaprilat. Investigational, Nutraceutical Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Enalaprilat. Approved Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Enalaprilat. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Enalaprilat. Experimental Felodipine Felodipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Enalaprilat. Approved Fenoldopam Fenoldopam may increase the hypotensive activities of Enalaprilat. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Enalaprilat. Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Enalaprilat. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Enalaprilat. Experimental Ferulic acid Ferulic acid may increase the hypotensive activities of Enalaprilat. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Enalaprilat. Approved, Investigational Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Enalaprilat. Approved, Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Enalaprilat. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Enalaprilat. Experimental Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Enalaprilat. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Enalaprilat. Experimental Fosinopril Fosinopril may increase the hypotensive activities of Enalaprilat. Approved Fostamatinib Fostamatinib may increase the antihypertensive activities of Enalaprilat. Approved, Investigational Furazolidone Furazolidone may increase the hypotensive activities of Enalaprilat. Approved, Investigational, Vet Approved Furosemide Furosemide may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Garlic The serum concentration of Enalaprilat can be decreased when it is combined with Garlic. Approved, Nutraceutical Guacetisal The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Guacetisal. Experimental Guanabenz Guanabenz may increase the hypotensive activities of Enalaprilat. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Enalaprilat. Approved Guanazodine Enalaprilat may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Guanethidine may increase the hypotensive activities of Enalaprilat. Approved Guanfacine Guanfacine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Guanoclor Enalaprilat may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Enalaprilat may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Enalaprilat may increase the hypotensive activities of Guanoxan. Experimental Halothane The risk or severity of adverse effects can be increased when Enalaprilat is combined with Halothane. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Enalaprilat. Experimental Hemoglobin crosfumaril The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Hemoglobin crosfumaril. Experimental Heparin The risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Heparin. Approved, Investigational Hexamethonium Hexamethonium may increase the hypotensive activities of Enalaprilat. Experimental Hexobarbital Hexobarbital may increase the hypotensive activities of Enalaprilat. Approved Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Enalaprilat. Investigational Hydracarbazine Hydracarbazine may increase the hypotensive activities of Enalaprilat. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Enalaprilat. Approved Hydrochlorothiazide The risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Enalaprilat. Approved, Vet Approved Hydroflumethiazide The risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Enalaprilat. Approved, Investigational Ibuprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Enalaprilat. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Enalaprilat. Withdrawn Icatibant Icatibant may decrease the antihypertensive activities of Enalaprilat. Approved, Investigational Iloprost The risk or severity of adverse effects can be increased when Enalaprilat is combined with Iloprost. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Enalaprilat is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Enalaprilat. Experimental Imipramine The serum concentration of Imipramine can be increased when it is combined with Enalaprilat. Approved Indapamide The risk or severity of hypotension can be increased when Indapamide is combined with Enalaprilat. Approved Indenolol Indenolol may increase the hypotensive activities of Enalaprilat. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Enalaprilat. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Enalaprilat. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Enalaprilat. Withdrawn Indoramin Indoramin may increase the hypotensive activities of Enalaprilat. Withdrawn Iprindole The serum concentration of Iprindole can be increased when it is combined with Enalaprilat. Experimental Iproclozide Iproclozide may increase the hypotensive activities of Enalaprilat. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Enalaprilat. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Enalaprilat. Approved, Investigational Iron Iron can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Iron Dextran The risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron Dextran. Approved, Vet Approved Isocarboxazid Isocarboxazid may increase the hypotensive activities of Enalaprilat. Approved Isoflurane The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoflurane. Approved, Vet Approved Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Mononitrate. Approved Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Enalaprilat. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Enalaprilat. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Enalaprilat. Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Enalaprilat. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Enalaprilat. Approved Lacidipine Enalaprilat may increase the hypotensive activities of Lacidipine. Approved, Investigational Lanthanum carbonate The serum concentration of Enalaprilat can be decreased when it is combined with Lanthanum carbonate. Approved Latanoprost Latanoprost may increase the hypotensive activities of Enalaprilat. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Enalaprilat. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Levobupivacaine. Approved, Investigational Levodopa Enalaprilat may increase the orthostatic hypotensive activities of Levodopa. Approved Levosimendan The risk or severity of adverse effects can be increased when Enalaprilat is combined with Levosimendan. Approved, Investigational Linagliptin The risk or severity of adverse effects can be increased when Linagliptin is combined with Enalaprilat. Approved Linsidomine Enalaprilat may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Enalaprilat. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Enalaprilat. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with Enalaprilat. Experimental Lofepramine The serum concentration of Lofepramine can be increased when it is combined with Enalaprilat. Experimental Lofexidine Lofexidine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Enalaprilat. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Enalaprilat. Approved, Investigational Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Enalaprilat. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Enalaprilat. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Enalaprilat. Approved, Investigational Macitentan Enalaprilat may increase the hypotensive activities of Macitentan. Approved Magnesium carbonate Magnesium carbonate can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Enalaprilat. Approved Magnesium Trisilicate Magnesium Trisilicate can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Manidipine Manidipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Mannitol. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Enalaprilat. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Enalaprilat. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalaprilat. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Enalaprilat. Approved Melitracen The serum concentration of Melitracen can be increased when it is combined with Enalaprilat. Experimental, Investigational Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Enalaprilat. Approved, Vet Approved Mesalazine The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Mesalazine. Approved Mestranol The serum concentration of Mestranol can be decreased when it is combined with Enalaprilat. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Enalaprilat. Approved, Investigational, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Methazolamide. Approved Methohexital Methohexital may increase the hypotensive activities of Enalaprilat. Approved Methoserpidine Enalaprilat may increase the hypotensive activities of Methoserpidine. Experimental Methyclothiazide The risk or severity of hypotension can be increased when Methyclothiazide is combined with Enalaprilat. Approved Methyl salicylate The risk or severity of renal failure can be increased when Methyl salicylate is combined with Enalaprilat. Approved, Vet Approved Methyldopa Methyldopa may increase the hypotensive activities of Enalaprilat. Approved Methylene blue Methylene blue may increase the hypotensive activities of Enalaprilat. Approved, Investigational Methylergometrine The serum concentration of Methylergometrine can be increased when it is combined with Enalaprilat. Approved Methylphenidate Methylphenidate may decrease the antihypertensive activities of Enalaprilat. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Enalaprilat. Approved Metipranolol Metipranolol may increase the hypotensive activities of Enalaprilat. Approved Metolazone The risk or severity of hypotension can be increased when Metolazone is combined with Enalaprilat. Approved Metoprolol Metoprolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Metyrosine Enalaprilat may increase the hypotensive activities of Metyrosine. Approved Mibefradil Mibefradil may increase the hypotensive activities of Enalaprilat. Investigational, Withdrawn Midazolam The serum concentration of Midazolam can be increased when it is combined with Enalaprilat. Approved, Illicit Minaprine Minaprine may increase the hypotensive activities of Enalaprilat. Approved Minoxidil Minoxidil may increase the hypotensive activities of Enalaprilat. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Enalaprilat. Investigational Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Enalaprilat. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Enalaprilat. Approved, Investigational Moexipril Moexipril may increase the hypotensive activities of Enalaprilat. Approved Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Enalaprilat. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Morphine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Morphine. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Muzolimine Enalaprilat may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Enalaprilat. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Enalaprilat. Approved Nabilone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabilone. Approved, Investigational Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Enalaprilat. Approved Nadolol Nadolol may increase the hypotensive activities of Enalaprilat. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Enalaprilat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Enalaprilat. Approved Naftopidil Enalaprilat may increase the hypotensive activities of Naftopidil. Investigational Naproxen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Enalaprilat. Approved, Vet Approved Nebivolol Nebivolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Nefazodone The serum concentration of Nefazodone can be increased when it is combined with Enalaprilat. Approved, Withdrawn Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Enalaprilat. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nesiritide. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Enalaprilat. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Nicorandil Nicorandil may increase the vasodilatory activities of Enalaprilat. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nifedipine. Approved Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Enalaprilat. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Enalaprilat. Approved Niguldipine Niguldipine may increase the hypotensive activities of Enalaprilat. Experimental Nilvadipine Nilvadipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Nimesulide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Enalaprilat. Approved, Investigational, Withdrawn Nimodipine Nimodipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Enalaprilat. Approved Nitrendipine Nitrendipine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitric Oxide. Approved Nitroaspirin The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Nitroaspirin. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Enalaprilat. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitrous acid. Approved, Investigational Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Enalaprilat. Approved Obinutuzumab Enalaprilat may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Enalaprilat. Withdrawn Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Enalaprilat. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Enalaprilat. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Enalaprilat. Approved Omapatrilat Omapatrilat may increase the hypotensive activities of Enalaprilat. Investigational Omeprazole Omeprazole can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Opipramol The serum concentration of Opipramol can be increased when it is combined with Enalaprilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Enalaprilat. Vet Approved Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Enalaprilat. Approved Oxprenolol Oxprenolol may increase the hypotensive activities of Enalaprilat. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Enalaprilat. Approved, Withdrawn Paclitaxel The risk or severity of adverse effects can be increased when Enalaprilat is combined with Paclitaxel. Approved, Vet Approved Palmidrol The risk or severity of adverse effects can be increased when Palmidrol is combined with Enalaprilat. Experimental, Nutraceutical Papaverine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Papaverine. Approved, Investigational Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Enalaprilat. Approved Pargyline Pargyline may increase the hypotensive activities of Enalaprilat. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Enalaprilat. Approved, Investigational Patent Blue The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Patent Blue. Approved Penbutolol Penbutolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Pentobarbital Pentobarbital may increase the hypotensive activities of Enalaprilat. Approved, Investigational, Vet Approved Pentolinium Pentolinium may increase the hypotensive activities of Enalaprilat. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Enalaprilat. Approved, Investigational Perindopril Perindopril may increase the hypotensive activities of Enalaprilat. Approved Pethidine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pethidine. Approved Phenelzine Phenelzine may increase the hypotensive activities of Enalaprilat. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Enalaprilat. Withdrawn Phenobarbital Phenobarbital may increase the hypotensive activities of Enalaprilat. Approved, Investigational Phenoxybenzamine Phenoxybenzamine may increase the hypotensive activities of Enalaprilat. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Enalaprilat. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Enalaprilat. Approved Phenyl aminosalicylate The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Phenyl aminosalicylate. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Enalaprilat. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Enalaprilat. Approved, Investigational Pinacidil Pinacidil may increase the hypotensive activities of Enalaprilat. Approved Pindolol Pindolol may increase the hypotensive activities of Enalaprilat. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pipamperone. Approved, Investigational Piretanide Piretanide may increase the hypotensive activities of Enalaprilat. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Enalaprilat. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Enalaprilat. Approved Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Enalaprilat. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Enalaprilat. Experimental Pivhydrazine Pivhydrazine may increase the hypotensive activities of Enalaprilat. Withdrawn Platelet Activating Factor Platelet Activating Factor may increase the hypotensive activities of Enalaprilat. Experimental Polythiazide The risk or severity of hypotension can be increased when Polythiazide is combined with Enalaprilat. Approved Potassium bicarbonate Potassium bicarbonate may increase the hyperkalemic activities of Enalaprilat. Approved Potassium cation Potassium may increase the hyperkalemic activities of Enalaprilat. Approved, Investigational Potassium Chloride The risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Enalaprilat. Approved, Withdrawn Potassium Citrate Potassium Citrate may increase the hyperkalemic activities of Enalaprilat. Approved, Investigational, Vet Approved Pramipexole The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pramipexole. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Enalaprilat. Experimental, Investigational Prazosin Prazosin may increase the hypotensive activities of Enalaprilat. Approved Pregabalin The risk or severity of angioedema can be increased when Enalaprilat is combined with Pregabalin. Approved, Illicit, Investigational Primidone Primidone may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Procaine Procaine may increase the hypotensive activities of Enalaprilat. Approved, Investigational, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Enalaprilat. Experimental Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Enalaprilat. Approved, Investigational Propafenone The risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Propafenone. Approved Propofol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Propofol. Approved, Investigational, Vet Approved Propranolol Enalaprilat may increase the hypotensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Enalaprilat. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Enalaprilat. Experimental Protriptyline The serum concentration of Protriptyline can be increased when it is combined with Enalaprilat. Approved PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Enalaprilat. Investigational Quetiapine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Quetiapine. Approved Quinapril Quinapril may increase the hypotensive activities of Enalaprilat. Approved, Investigational Quinethazone The risk or severity of hypotension can be increased when Quinethazone is combined with Enalaprilat. Approved Quinine Quinine may increase the hypotensive activities of Enalaprilat. Approved Ramipril Ramipril may increase the hypotensive activities of Enalaprilat. Approved Rasagiline Rasagiline may increase the hypotensive activities of Enalaprilat. Approved Remifentanil The risk or severity of adverse effects can be increased when Enalaprilat is combined with Remifentanil. Approved Remikiren Remikiren may increase the hypotensive activities of Enalaprilat. Approved Rescinnamine Enalaprilat may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Enalaprilat. Approved, Experimental, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Riociguat The serum concentration of Riociguat can be increased when it is combined with Enalaprilat. Approved Risperidone Enalaprilat may increase the hypotensive activities of Risperidone. Approved, Investigational Rituximab Enalaprilat may increase the hypotensive activities of Rituximab. Approved Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Enalaprilat. Approved, Investigational, Withdrawn Ropinirole The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropivacaine. Approved Rotigotine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Rotigotine. Approved Sacubitril The risk or severity of angioedema can be increased when Enalaprilat is combined with Sacubitril. Approved Safrazine Safrazine may increase the hypotensive activities of Enalaprilat. Withdrawn Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Enalaprilat. Approved Salicylic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Enalaprilat. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Enalaprilat. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Enalaprilat. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Enalaprilat. Investigational Saxagliptin The risk or severity of angioedema can be increased when Saxagliptin is combined with Enalaprilat. Approved Secobarbital Secobarbital may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Enalaprilat. Approved, Investigational, Vet Approved Selexipag Enalaprilat may increase the hypotensive activities of Selexipag. Approved Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Enalaprilat. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Enalaprilat. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Enalaprilat. Investigational Sevoflurane The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sevoflurane. Approved, Vet Approved Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Enalaprilat. Approved, Investigational Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Enalaprilat. Approved Sirolimus The risk or severity of angioedema can be increased when Sirolimus is combined with Enalaprilat. Approved, Investigational Sitagliptin The risk or severity of angioedema can be increased when Sitagliptin is combined with Enalaprilat. Approved, Investigational Sitaxentan Enalaprilat may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium aurothiomalate The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Enalaprilat is combined with Sodium aurothiomalate. Approved, Investigational Sodium phosphate, monobasic The risk or severity of nephrotoxicity can be increased when Enalaprilat is combined with Sodium phosphate, monobasic. Approved Sotalol The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sotalol. Approved Spirapril Spirapril may increase the hypotensive activities of Enalaprilat. Approved Spironolactone The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Enalaprilat. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Enalaprilat. Investigational St. John's Wort The metabolism of Enalaprilat can be increased when combined with St. John's Wort. Approved, Investigational, Nutraceutical Streptokinase The risk or severity of adverse effects can be increased when Enalaprilat is combined with Streptokinase. Approved, Investigational Sufentanil The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil. Approved, Investigational Sulfasalazine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Enalaprilat. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Enalaprilat. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Enalaprilat. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Enalaprilat. Experimental Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Enalaprilat. Approved, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Enalaprilat. Approved, Investigational Talinolol Enalaprilat may increase the hypotensive activities of Talinolol. Investigational Tamsulosin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tamsulosin. Approved, Investigational Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Enalaprilat. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Enalaprilat. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Enalaprilat. Approved, Investigational Temocapril Temocapril may increase the hypotensive activities of Enalaprilat. Experimental, Investigational Temsirolimus The risk or severity of adverse effects can be increased when Enalaprilat is combined with Temsirolimus. Approved Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Enalaprilat. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Enalaprilat. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Enalaprilat. Vet Approved Terazosin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Terazosin. Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Enalaprilat. Approved Terlipressin Terlipressin may increase the hypotensive activities of Enalaprilat. Approved, Investigational Tetrahydropalmatine Enalaprilat may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Enalaprilat is combined with Thalidomide. Approved, Investigational, Withdrawn Theodrenaline Enalaprilat may increase the hypotensive activities of Theodrenaline. Investigational Theophylline The serum concentration of Theophylline can be decreased when it is combined with Enalaprilat. Approved Thiamylal Thiamylal may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Thiopental Thiopental may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Enalaprilat is combined with Thioridazine. Approved, Withdrawn Tianeptine The serum concentration of Tianeptine can be increased when it is combined with Enalaprilat. Approved, Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Enalaprilat. Approved Tibolone Tibolone may increase the hypotensive activities of Enalaprilat. Approved, Investigational Ticrynafen Ticrynafen may increase the hypotensive activities of Enalaprilat. Withdrawn Timolol Timolol may increase the hypotensive activities of Enalaprilat. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Enalaprilat. Investigational Tipranavir The serum concentration of Enalaprilat can be decreased when it is combined with Tipranavir. Approved, Investigational Tizanidine The risk or severity of hypotension can be increased when Tizanidine is combined with Enalaprilat. Approved, Investigational Tolazoline Tolazoline may increase the hypotensive activities of Enalaprilat. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolcapone. Approved, Withdrawn Tolfenamic Acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Enalaprilat. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Enalaprilat. Approved Tolonidine Enalaprilat may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Enalaprilat. Approved Tolvaptan Tolvaptan may increase the hyperkalemic activities of Enalaprilat. Approved Torasemide Torasemide may increase the hypotensive activities of Enalaprilat. Approved Trandolapril Trandolapril may increase the hypotensive activities of Enalaprilat. Approved Tranylcypromine Tranylcypromine may increase the hypotensive activities of Enalaprilat. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Enalaprilat. Approved Treprostinil Treprostinil may increase the hypotensive activities of Enalaprilat. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Enalaprilat is combined with Tretinoin. Approved, Investigational, Nutraceutical Triamterene Triamterene may increase the hyperkalemic activities of Enalaprilat. Approved Triazolam The serum concentration of Triazolam can be increased when it is combined with Enalaprilat. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Enalaprilat. Experimental Trichlormethiazide The risk or severity of hypotension can be increased when Trichlormethiazide is combined with Enalaprilat. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Enalaprilat. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Enalaprilat. Approved, Investigational Trimethoprim Trimethoprim may increase the hyperkalemic activities of Enalaprilat. Approved, Vet Approved Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Enalaprilat. Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Enalaprilat. Investigational Trolamine salicylate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Enalaprilat. Approved Udenafil Udenafil may increase the antihypertensive activities of Enalaprilat. Approved, Investigational Unoprostone Unoprostone may increase the hypotensive activities of Enalaprilat. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Enalaprilat. Investigational Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Enalaprilat. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Enalaprilat. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Enalaprilat. Approved Verapamil The risk or severity of adverse effects can be increased when Enalaprilat is combined with Verapamil. Approved Vildagliptin The risk or severity of adverse effects can be increased when Vildagliptin is combined with Enalaprilat. Approved, Investigational Vincamine Enalaprilat may increase the hypotensive activities of Vincamine. Experimental Xipamide Enalaprilat may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Xylometazoline may increase the hypotensive activities of Enalaprilat. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Enalaprilat. Approved, Investigational, Vet Approved Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Enalaprilat. Approved, Investigational Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Enalaprilat. Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Enalaprilat. Approved, Investigational, Withdrawn Zofenopril Enalaprilat may increase the hypotensive activities of Zofenopril. Experimental Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Enalaprilat. Withdrawn - Food Interactions
- Not Available
References
- General References
- Ulm EH: Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. Drug Metab Rev. 1983;14(1):99-110. [PubMed:6301792]
- Davies RO, Gomez HJ, Irvin JD, Walker JF: An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol. 1984;18 Suppl 2:215S-229S. [PubMed:6099737]
- External Links
- Human Metabolome Database
- HMDB0041886
- KEGG Drug
- D03769
- KEGG Compound
- C11720
- PubChem Compound
- 5462501
- PubChem Substance
- 347827859
- ChemSpider
- 4575429
- BindingDB
- 50367254
- ChEBI
- 4786
- ChEMBL
- CHEMBL577
- HET
- EAL
- RxList
- RxList Drug Page
- Wikipedia
- Enalaprilat
- AHFS Codes
- 24:32.04 — Angiotensin-converting Enzyme Inhibitors
- PDB Entries
- 1uze / 2x90
- FDA label
- Download (2.99 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Congestive Cardiomyopathy / High Blood Pressure (Hypertension) 1 4 Completed Basic Science Type 2 Diabetes Mellitus 1 Not Available Completed Not Available Salt-sensitive Hypertension 1 Not Available Completed Health Services Research Idiopathic orthostatic hypotension / Spinal Cord Injuries (SCI) 1 Not Available Completed Treatment CVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages 1 Not Available Completed Treatment High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Injection Intravenous 1.25 mg/mL Injection Intravenous 2.5 mg/2mL Injection, solution Intravenous 1.25 mg/mL Solution Intravenous 1.25 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.876 mg/mL ALOGPS logP -0.09 ALOGPS logP -1.1 ChemAxon logS -2.6 ALOGPS pKa (Strongest Acidic) 3.13 ChemAxon pKa (Strongest Basic) 7.83 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 106.94 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 90.06 m3·mol-1 ChemAxon Polarizability 35.82 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Dipeptides
- Alternative Parents
- Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides show 8 more
- Substituents
- Alpha-dipeptide / N-acyl-alpha-amino acid / Proline or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / N-acylpyrrolidine show 26 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- dipeptide, dicarboxylic acid (CHEBI:4786)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
- Gene Name
- ACE
- Uniprot ID
- P12821
- Uniprot Name
- Angiotensin-converting enzyme
- Molecular Weight
- 149713.675 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Peptide binding
- Specific Function
- This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation.
- Gene Name
- BDKRB1
- Uniprot ID
- P46663
- Uniprot Name
- B1 bradykinin receptor
- Molecular Weight
- 40494.29 Da
References
- Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG: Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem. 2002 May 10;277(19):16847-52. Epub 2002 Mar 5. [PubMed:11880373]
Drug created on November 30, 2015 12:10 / Updated on August 14, 2018 04:32